External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Szkandera, Joanna ^a   Stotz, Michael ^a   Eisner, Florian ^a   Absenger, Gudrun ^a   Stojakovic, Tatjana ^a   Samonigg, Hellmut ^a   Kornprat, Peter ^a   Schaberl Moser, Renate ^a   AlZoughbi, Wael ^a   Ress, Anna Lena ^a   Seggewies, Friederike Sophia ^a   Gerger, Armin ^a   Hoefler, Gerald ^a   Pichler, Martin ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL EVALUATION; DERIVED NEUTROPHIL TO LYMPHOCYTE RATIO; EXTERNAL VALIDITY; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; RETROSPECTIVE STUDY; SURVIVAL TIME; VALIDATION PROCESS;

AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84892620293     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078225     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
4. Tinchon C, Hubmann E, Pichler A, Keil F, Pichler M, et al. (2013) Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol 52(6):1231-3.
5. Cubilla AL, Fortner J, Fitzgerald PJ (1978) Lymph node involvement in carcinoma of the head of the pancreas area. Cancer 41: 880-887.
6. Nagakawa T, Kayahara M, Ohta T, Ueno K, Konishi I, et al. (1991) Patterns of neural and plexus invasion of human pancreatic cancer and experimental cancer. Int J Pancreatol 10: 113-119.
7. Fortner JG, Klimstra DS, Senie RT, Maclean BJ (1996) Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 223: 147-153.
8. Griffanti-Bartoli F, Arnone GB, Ceppa P, Ravera G, Carrabetta S, et al. (1994) Malignant tumors in the head of the pancreas and the periampullary region. Diagnostic and prognostic aspects. Anticancer Res 14: 657-666.
9. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, et al. (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246: 52-60.
10. Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, et al. (1999) The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 29: 16-22.
11. Bleeker SE, Moll HA, Steyerberg EW, Donders AR, Derksen-Lubsen G, et al. (2003) External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 56: 826-832.
12. Hanahan D,Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
13. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.
14. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867.
15. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91: 181-184.
16. Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, et al. (2013) Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 108: 901-907.
17. Szkandera J, Absenger G, Liegl-Atzwanger B, Pichler M, Stotz M, et al. (2013) Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br J Cancer 108(8): 1677-83.
18. Yao Y, Yuan D, Liu H, Gu X, Song Y (2013) Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother 62: 471-479.
19. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, et al. (2012) Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol 29: 3092-3100.
20. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, et al. (2013) Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013 109(2): 416-21.
21. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107: 695-699.
22. Stotz M, Eisner F, Szkandera J, Absenger G, Kornprat P, et al. (2013) Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series. J Clin Pathol, in press.
23. Edge SB, Byrd DR, Compton CC, et al. (2010) Exocrine and endocrine pancreas. In: AJCC Cancer Staging Manual. 7th ed. New York: Springer. 241-249 p.
24. Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, et al. (2013) A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 23;109(2): 395-400.
25. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003) Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6: 283-287.
26. Ulich TR, del Castillo J, Keys M, Granger GA, Ni RX (1987) Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 139: 3406-3415.
27. Ulich TR, del Castillo J, Guo KZ (1989) In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood 73: 108-10.
28. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, et al. (2009) Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 45: 1950-1958.
29. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
30. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
31. Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A (1987) Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 47: 173-177.
32. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, et al. (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8: 2553-2562.
33. Zikos TA, Donnenberg AD, Landreneau RJ, Luketich JD, Donnenberg VS (2011) Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother 60: 819-827.
34. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380-384.
35. Petrie HT, Klassen LW, Kay HD (1985) Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 134: 230-234.
36. Shau HY, Kim A (1988) Suppression of lymphokine-activated killer induction by neutrophils. J Immunol 141: 4395-4402.